- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Genes Could Predict
The NIH-funded study, published in the New England Journal of Medicine, identified mutations that are harbored early and could be potential early-onset biomarkers for detection.
Many older people silently harbor a blood "pre-cancer" — a gene mutation acquired during their lifetime that could start them on the path to leukemia, lymphoma or other blood disease, scientists have discovered. It opens a new frontier on early detection and possibly someday preventing these cancers, which become more common with age.
The discovery was made by two international research teams working independently, decoding the DNA of about 30,000 people.
The gene mutations were rare in people under 40, but found in about 10 percent of those over 65 and in nearly 20 percent of folks over 90.
Having one of the mutations does not destine someone to develop a blood cancer, but it raises the risk of that more than tenfold. It also increases the chance of a heart attack or stroke, and of dying from any cause over the next four to eight years.
"We are hopeful that someday we would be able to use this as a screening test and identify individuals who are at risk," said one study leader, Dr. Benjamin Ebert of Brigham and Women's Hospital in Boston.
Link to the news story on Denver Post: http://dpo.st/12jVX6D
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Decisions and Precision in Value-Based Cancer Care
January 7th 2025An Institute for Value-Based Medicine regional event in Houston, Texas, covered inconsistencies with the integration of precision medicine in oncology practices, the evolution of treatment for multiple myeloma, and more.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers
January 2nd 2025Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.
Read More
